Table of Contents
- Foreword
- Executive Summary
- Cardiovascular Disease
- Mortality
- Prevention and Treatment
- Drugs in the Pipeline
- Competitor Ratio Analysis
- Cholesterol and Triglycerides
- The Cholesterol Management Drugs Market
- Statins
- NICE Guidance on the use of statins
- Lipitor (atorvastatin)
- Patents, Generic Competition & Litigation
- US
- Canada
- Austria
- Denmark
- Finland
- Ireland
- Norway
- Spain
- UK
- Australia
- Andean Pact countries
- Sales Forecast
- Clinical Trials
- SPARCL
- Imaging studies: ILLUSTRATE and RADIANCE
- Pfizer' s response to the ASTEROID trial
- TNT
- ASCOT
- ASCOT-LLA (Anglo-Scandinavian Cardiac Outcomes Trial: Lipid-Lowering Arm)
- CARDS
- IDEAL - atorvastatin versus simvastatin
- Atorvastatin+rosiglitazone in diabetic patients
- Lescol (fluvastatin)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Crestor (rosuvastatin)
- Patents, Generic Competition & Litigation
- Safety Issues
- Patient data demonstrate efficacy of Crestor
- Sales Forecast
- Clinical Trials
- ASTEROID
- METEOR
- MERCURY II
- EXPLORER
- Effect of rosuvastatin on C-reactive protein and renal function
- Crestor in combination with ezetimibe
- LDL-C reductions - Crestor versus Pravachol and Zocor
- Zocor (simvastatin)
- Generic Competition
- Sales Forecast
- Clinical Trials
- SAFARI - simvastatin+fenofibrate
- 4S
- Heart Protection Study
- Other Antihyperlipidaemic Agents
- Zetia (ezetimibe)
- NICE guidance on ezetimibe
- Patents, Generic Competition & Litigation
- Sales Forecast
- Clinical Trials
- EXPLORER
- Co-administration of ezetimibe+fenofibrate
- EASE
- TriCor (fenofibrate)
- Patents, Litigation & Generic Competition
- Lipofen (fenofibrate)
- Fenoglide (fenofibrate)
- Sales Forecast
- Clinical Trials
- TriCor (fenofibrate) & WelChol (colesevelam)
- Niaspan (niacin)
- Patents & Litigation
- Sales Forecast
- Clinical Trials
- Niaspan combined with aspirin
- COMPELL
- Combination Products
- Vytorin (ezetimibe+simvastatin)
- FDA issues early communication regarding ongoing review of Vytorin
- Patents
- Sales Forecast
- Clinical Trials
- ENHANCE
- IMPROVE-IT
- Vytorin versus Lipitor (atorvastatin) in Type II diabetes patients
- Combined post hoc analysis of three studies
- VYVA
- Caduet (amlodipine+atorvastatin)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Recent Approval and Drugs in Development
- Simcor
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Tredaptive (niacin+laropiprant)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Phase III
- Tredaptive co-administered with simvastatin
- MK-0524B (simvastatin+niacin+laropiprant)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- MK-0452B versus atorvastatin
- MK-0452B versus MK-0452A+simvastatin
- TriLipix (ABT-335)
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Anacetrapib
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Outlook
- Clinical Trials
- AEGR-733
- Competitor ratio analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Outlook
- Clinical Trials
- Phase II
- Homozygous Familial Hypercholesterolaemia
- Hypertension
- The Hypertension Drugs Market
- Angiotensin-II Receptor Blockers
- Aprovel (irbesartan)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Diovan/Co-Diovan (valsartan/valsartan+HCTZ)
- Patents, Generic Competition & Litigation
- Sales Forecast
- Clinical Trials
- NAVIGATOR
- AADVANCE
- VALUE
- Val-HeFT
- Cozaar/Hyzaar (losartan/losartan+HCTZ)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Micardis/MicardisPlus (telmisartan/telmisartan+HCTZ)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- SURGE-2
- PRISMA
- ONTARGET/TRANSCEND
- PROTECTION
- PROTECTION Study Programme - AMADEO
- PROTECTION Study Programme - DETAIL
- PROTECTION Study Programme - ESPRIT
- PROTECTION Study Programme - ATHOS
- PROTECTION Study Programme - INNOVATION
- Atacand (candesartan cilexetil)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- HIJ-CREATE
- TROPHY
- CHARM
- DIRECT
- Switching from losartan to candesartan cilexetil: an observational study in the UK
- Benicar (olmesartan)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- MORE
- BEST & Treatment of Stage I and Stage II Hypertension Studies
- Dihydropyridine Calcium Channel Blockers
- Norvasc (amlodipine)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Adalat (nifedipine)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Zanidip (lercanidipine)
- ACE Inhibitors
- Vasotec (enalapril)
- Generic Competition
- Sales Forecast
- Altace/Delix/Tritace (ramipril)
- Combinations
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Beta Blockers
- Coreg (carvedilol)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Seloken/Toprol-XL (metoprolol succinate)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Alpha Adreno-Receptor Antagonists
- Cardura (doxazosin)
- Combination Products
- Lotrel (amlodipine+benazepril)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- ACCOMPLISH
- LOGIC, SHIELD and ALERT
- Azor (amlodipine+olmesartan)
- Zanipress (lercanidipine+enalapril)
- Recent Approvals and Drugs in Development
- Rasilez/Tekturna (aliskiren)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- ALLAY
- Phase III Results
- Phase II Results
- Bystolic (nebivolol)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Bystolic in African-American patients with Stage I-II HT
- Patients with mild-to-moderate HT
- Darusentan
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Cleviprex (clevidipine)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Ilepatril
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Coronary Artery Disease
- Genetic variations may increase risk of CAD
- Angina
- Recent Approvals and Drugs in Development
- Crestor: first statin to achieve atherosclerosis regression by QCA in a major clinical trial
- Ranexa (ranolazine)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Ranolazine in LQT3
- MERLIN TIMI-36
- ERICA
- CARISA
- MARISA
- Procoralan (ivabradine)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Procoralan versus amlodipine in patients with stable CAD
- BEAUTIFUL
- Generx (alferminogene tadenovec, Ad5FGF-4)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Experimental Stem Cell Therapy
- Atrial Fibrillation
- Current Treatments
- Cordarone (amiodarone)
- Rythmol (propafenone)
- Tambocor (flecainide)
- Corvert (ibutilide fumarate)
- Tikosyn (dofetilide)
- Drugs in Development
- Multaq (dronedarone)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Pulzium (tedisamil)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Vernakalant (RSD1235)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- ACT 1
- ACT 3
- Phase IIb study of oral vernakalant
- Pulmonary Arterial Hypertension
- Tracleer (bosentan)
- Sales Forecast
- Clinical Trials
- COMPASS-1 and EARLY
- BUILD Programme
- BREATHE-5
- Paediatric Study
- TRAX PMS
- Ventavis (iloprost)
- Sales Forecast
- Clinical Trials
- VISION
- STEP
- Long-term safety and efficacy
- ACTIVE
- Revatio (sildenafil)
- Sales Forecast
- Clinical Trials
- Australian Trial in Heart Failure
- Thelin (sitaxsentan)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Eisenmenger syndrome - observational data
- Long-term treatment
- STRIDE-2
- STRIDE-2X
- STRIDE-4
- Letairis/Volibris (ambrisentan)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- Viveta (treprostinil)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Treprostinil in AERx Essence delivery system
- TRIUMPH-1
- Inhaled treprostinil as add-on therapy
- Thrombosis
- Thrombosis Drugs Market
- Lovenox (enoxaparin)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- ExTRACT-TIMI 25
- STEEPLE
- SYNERGY
- Arixtra (fondaparinux)
- Patents & Generic Competition
- Sales Forecasts
- Clinical Trials
- OASIS- 5
- OASIS 6
- ARTEMIS
- FLEXTRA
- PEGASUS
- Plavix (clopidogrel)
- Patents & Generic Competition
- Sales Forecast
- Clinical Trials
- Individualised loading study
- BRAVE-3
- CHARISMA
- ACTIVE
- Recent Approval and Drugs in Development
- Pradaxa (dabigatran)
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- RE-VOLUTION (RE-MODEL, RE-MOBILIZE and RE-NOVATE)
- Prasugrel
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- TRITON-TIMI 38
- Early-phase data
- Rivaroxaban
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- RECORD2
- RECORD3
- Phase ll studies
- Apixaban
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Sales Forecast
- Clinical Trials
- M118
- Competitor Ratio Analysis
- Novelty/rationale for mechanism of action
- Proof of concept/clinical data
- Management/clinical expertise
- Competition within the marketplace
- Risks associated with drug development in therapeutic class
- Clinical Trials
- Abbreviations
- SOURCES
- Espicom Sources
- Others
List of Tables
- Deaths from Ischaemic Heart Diseases in Selected Markets, 2005
- Deaths from Acute Myocardial Infarction in Major Markets, 2005
- Deaths from Diseases of the Pulmonary Circulation and Other Forms of Heart
Disease, 2005
- Leading Cardiovascular Drugs by Sales Value, 2006-2007 (US$ Million)
- US Patent Expiry for Major Cardiovascular Drugs
- Launched Products in Development
- Novel Drugs in Development
- Competitor Ratio Analysis Summary
- Sales of Leading Cholesterol Management Drugs, 2006-2007 (US$ Million)
- Sales of Leading Statins, 2003-2007 (US$ Million)
- Lipitor Sales, 2003-2012 (US$ Million)
- Lipitor US Patents
- Lescol Sales, 2003-2007 (US$ Million)
- Lescol US Patents
- Crestor Sales, 2003-2007 (US$ Million)
- Crestor US Patents
- Zocor Sales, 2003-2007 (US$ Million)
- Zetia Sales, 2003-2007 (US$ Million)
- Zetia US Patents
- TriCor Sales, 2003-2007 (EUR & US$ Million)
- TriCor US Patents
- Niaspan Sales, 2003-2007 (US$ Million)
- Niaspan US Patents
- Vytorin Sales, 2004-2007 (US$ Million)
- Vytorin US Patents
- Caduet Sales, 2004-2007 (US$ Million)
- Caduet US Patents
- Drugs in Development for Hypercholesterolaemia and Dyslipidaemia
- Sales of Leading Hypertension Drugs, 2006-2007 (US$ Million)
- Aprovel/Avapro/Karvea Sales, 2003-2007 (EUR & US$ Million)
- Avapro/Avalide US Patents
- Diovan/Co-Diovan Sales, 2003-2007 (US$ Million)
- Diovan US Patents
- Cozaar/Hyzaar Sales, 2003-2007 (US$ Million)
- Cozaar/Hyzaar US Patents
- Micardis Sales, 2003-2007 (EUR & US$ Million)
- Micardis Sales in Japan, 2003-2007 (¥ & US$ Million)
- Micardis US Patents
- Atacand Sales, 2003-2007 (US$ Million)
- Blopress Sales, 2003-2007 (¥ Billion & US$ Million)
- Atacand/Atacand Plus US Patents
- Benicar/Olmetec Sales, 2004-2007 (¥ Million & US$ Million)
- Benicar US Patents
- Norvasc Sales, 2003-2007 (US$ Million)
- Amlodin Sales, 2003-2007 (¥ Billion & US$ Million)
- Adalat Sales, 2003-2007 (EUR & US$ Million)
- Adalat US Patents
- Zanidip Sales, 2003-2007 (EUR & US$ Million)
- Vasotec/Vaseretic Sales, 2003-2007 (US$ Million)
- Altace/Delix/Tritace Sales, 2003-2007 (EUR & US$ Million)
- Altace US Patents
- Coreg/Dilatrend Sales, 2003-2007 (£/CHF & US$ Million)
- Coreg US Patents
- Seloken ZOK/Toprol-XL Sales, 2003-2007 (US$ Million)
- Cardura Sales, 2003-2007 (US$ Million)
- Lotrel Sales, 2003-2007 (US$ Million)
- Lotrel US Patents
- Drugs in Development for Hypertension
- Drugs in Development for Atherosclerosis and Coronary Artery Disease
- Drugs in Development for Atrial Fibrillation
- Drugs in Development for PAH
- Tracleer Sales, 2003-2007 (CHF & US$ Million)
- Sales of Leading Anticoagulant & Antiplatelet Drugs, 2006-2007 (US$
Million)
- Lovenox/Clexane Sales, 2003-2007 (EUR & US$ Million)
- Lovenox US Patents
- Arixtra Sales, 2004-2007 (£ & US$ Million)
- Plavix/Iscover Sales, 2003-2007 (EUR & US$ Million)
- Plavix US Patents
- Drugs in Development for Thrombosis
List of Figures
- Global Sales of Leading Statins, 2003-2007 (US$ Million)
- Lipitor Sales, 2003A-2012E (US$ Million)
- Lescol Sales 2003A-2012E (US$ Million)
- Crestor Sales, 2003A - 2012E (US$ Million)
- Zocor Sales 2003A-2012E (US$ Million)
- Zetia Sales 2003A-2012E (US$ Million)
- TriCor Sales, 2003A-2012E (US$ Million)
- Niaspan Sales, 2003A - 2012E (US$ Million)
- Vytorin Sales, 2004A-2012E (US$ Million)
- Caduet Sales 2004A-2012E (US$ Million)
- Simcor Projected Sales, 2008-2012 (US$ Million)
- Tredaptive Projected Sales, 2008-2012 (US$ Million)
- MK-0524B Projected Sales, 2009-2013 (US$ Million)
- TriLipix Projected Sales, 2010-2013 (US$ Million)
- Aprovel/Avapro Sales 2003A-2012E (US$ Million)
- Diovan/Co-Diovan Sales 2003A-2012E (US$ Million)
- Cozaar/Hyzaar Sales 2003A-2012E (US$ Million)
- Micardis Sales, 2003A-2012E (US$ Million)
- Atacand Sales, 2003A-2012E (US$ Million)
- Blopress Sales, 2003A-2012E (¥ Billion)
- Benicar/Olmetec Sales 2003A-2012E (US$ Million)
- Norvasc Sales, 2003A- 2012E (US$ Million)
- Amlodin Sales, 2003A-2012E (¥ Billion)
- Adalat Sales 2003A-2012E (US$ Million)
- Zanidip Sales 2003A-2012E (US$ Million)
- Vasotec/Vaseretic Sales 2003A-2012E (US$ Million)
- Altace/Tritace Sales 2003A-2012E (US$ Million)
- Coreg Sales, 2003A-2012E (US$ Million)
- Seloken/Toprol-XL Sales 2003A-2012E (US$ Million)
- Cardura Sales 2003A-2012E (US$ Million)
- Lotrel Sales, 2003A-2012E (US$ Million)
- Rasilez/Tekturna Projected Sales, 2007-2012 (US$ Million)
- Bystolic Projected Sales, 2008-2013 (US$ Million)
- Darusentan Projected Sales, 2009-2012 (US$ Million)
- Cleviprex Projected Sales, 2008-2013 (US$ Million)
- Ranexa Sales 2006A-2012E (US$ Million)
- Procoralan Sales, 2006E-2012E (US$ Million)
- Multaq Projected Sales, 2009E-2014E (US$ Million)
- Pulzium Projected Sales 2008E-2013E (US$ Million)
- Kynapid Projected Sales 2008E-2013E (US$ Million)
- Tracleer Sales, 2003A-2012E (US$ Million)
- Ventavis Sales, 2005A-2012E (US$ Million)
- Revatio Sales, 2005A-2012E (US$ Million)
- Thelin Sales, 2006A-2012E (US$ Million)
- Letairis/Volibris Projected Sales, 2008-2012 (US$ Million)
- Lovenox Sales, 2003A-2012E (US$ Million)
- Arixtra Sales, 2004A-2012E (US$ Million)
- Plavix/Iscover Sales, 2003A-2012E (US$ Million)
- Pradaxa Projected Sales, 2008-2013 (US$ Million)
- Prasugrel Projected Sales, 2008-2013 (US$ Million)
- Rivaroxaban Projected Sales, 2009-2014 (US$ Million)
- Apixaban Projected Sales, 2010-2014 (US$ Million)
|
Related Report
|
View Cart
